Land: Kanada
Sprache: Englisch
Quelle: Health Canada
DESLORATADINE; PSEUDOEPHEDRINE SULFATE
BAYER INC
R01BA52
PSEUDOEPHEDRINE, COMBINATIONS
2.5MG; 120MG
TABLET (EXTENDED-RELEASE)
DESLORATADINE 2.5MG; PSEUDOEPHEDRINE SULFATE 120MG
ORAL
2/4/7/10/14/20/30
OTC
SECOND GENERATION ANTIHISTAMINES
Active ingredient group (AIG) number: 0252460001; AHFS:
APPROVED
2014-12-05
_< AERIUS® SINUS + ALLERGY > _ _ _ _< Desloratadine 2.5 mg & Pseudoephedrine sulfate 120 mg> _ _Page 1 of 36_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION AERIUS® SINUS + ALLERGY Desloratadine and Pseudoephedrine sulfate Extended-Release Tablets Extended-release tablets, Desloratadine 2.5 mg / Pseudoephedrine Sulfate 120 mg, Oral Histamine H1 Receptor Antagonist / Sympathomimetic Amine Bayer Inc Date of Authorization: February 1 st , 2010 2920 Matheson Blvd. E Date of Revision: February 20 th , 2024 Mississauga, ON L4W 5R6 Submission Control Number: 278741 ® TM see www.bayer.ca/tm-mc _ _ _< AERIUS® SINUS + ALLERGY > _ _ _ _<_ _Desloratadine 2.5 mg & Pseudoephedrine sulfate 120 mg> _ _Page 2 of 36_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ........................................................................................................................... 4 1.1 Pediatrics ............................................................................................................................... 4 1.2 Geriatrics ............................................................................................................................... 4 2 CONTRAINDICATIONS ............................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................................... 4 4 DOSAGE AND ADMINISTRATION ............................................................................................ 5 4.1 Dosing Considerations .......................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ..................................................................... 5 4.4 Administration ............................... Lesen Sie das vollständige Dokument